Mankind ventured into the arena of biologics drug development in a focused manner with a well-defined strategy. A state-of-the-art research laboratory at our Integrated Research Centre houses latest equipment for process development and analytical characterization of highly complex biological drugs.
With a pool of talented scientists, the Mankind Biotechnology R&D has comprehensive capabilities for clone/cell line development, upstream and downstream process development, and analytical research.
Products based on recombinant proteins and mAbs are in focus for development of therapeutic products in the areas of auto-immune disorders, assisted reproductive therapy, and infertility treatment including other important disease areas.
Mankind's Drug Discovery Efforts are directed towards identifying and developing new therapies for disease areas that include Metabolic disorders, Liver and auto-immune disorders. Mankind’s focused and well defined strategy has enabled us to identify promising candidates and we are building a robust pipeline of molecules for our preclinical and clinical developments. This steady movement will ensure that at least one compound enters the clinical phase in terms of first-in-human studies each year. New Drug Discovery and Research (NDDR) Department has capabilities to conduct drug discovery & development from concept to IND enabling preclinical and clinical studies